CoChat

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

Coppé, Jean-Philippe, Mori, Miki, Pan, Bo, Yau, Christina, Wolf, Denise M., Ruiz-Saenz, Ana, Brunen, Diede, Prahallad, Anirudh, Cornelissen-Steijger, Paulien, Kemper, Kristel, Posch, Christian, Wang, Changjun, Dreyer, Courtney A., Krijgsman, Oscar, Lee, Pei Rong Evelyn, Chen, Zhongzhong, Peeper, Daniel S., Moasser, Mark M., Bernards, René, van ‘t Veer, Laura J. · 2019 · Nature Cell Biology
Cited by 36

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41556-019-0328-z

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 47

  1. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683–695 (2002). · DOI · Paper page
  2. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001). · DOI · Paper page
  3. Fleuren, E. D., Zhang, L., Wu, J. & Daly, R. J. The kinome ‘at large’ in cancer. Nat. Rev. Cancer 16, 83–98 (2016). · DOI · Paper page
  4. Johnson, S. A. & Hunter, T. Kinomics: methods for deciphering the kinome. Nat. Methods 2, 17–25 (2005). · DOI · Paper page
  5. Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A. & Ideker, T. The Cancer Cell Map Initiative: defining the hallmark networks of cancer. Mol. Cell 58, 690–698 (2015). · DOI · Paper page
  6. Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014). · DOI · Paper page
  7. Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014). · DOI · Paper page
  8. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015). · DOI · Paper page
  9. Drake, J. M. et al. Phosphoproteome integration reveals patient-specific networks in prostate. Cancer Cell 166, 1041–1054 (2016).
  10. Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8, 1583–1594 (2014). · DOI · Paper page
  11. Sos, M. L. et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 8, 1037–1048 (2014). · DOI · Paper page
  12. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007). · DOI · Paper page
  13. Kubota, K. et al. Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nat. Biotechnol. 27, 933–940 (2009). · DOI
  14. Nomura, D. K., Dix, M. M. & Cravatt, B. F. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10, 630–638 (2010). · DOI · Paper page
  15. Ren, W., Damayanti, N. P., Wang, X. & Irudayaraj, J. M. Kinase phosphorylation monitoring with i-motif DNA cross-linked SERS probes. Chem. Commun. (Camb.) 52, 410–413 (2016). · doi:10.1039/c5cc06566f
  16. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039–1045 (2011). · DOI · Paper page
  17. Houseman, B. T., Huh, J. H., Kron, S. J. & Mrksich, M. Peptide chips for the quantitative evaluation of protein kinase activity. Nat. Biotechnol. 20, 270–274 (2002). · DOI · Paper page
  18. Fang, C. et al. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res. 70, 8299–8308 (2010). · DOI
  19. Li, X. et al. The reverse in-gel kinase assay to profile physiological kinase substrates. Nat. Methods 4, 957–962 (2007). · doi:10.1038/nmeth1106
  20. Wu, J., Barbero, R., Vajjhala, S. & O’Connor, S. D. Real-time analysis of enzyme kinetics via micro parallel liquid chromatography. Assay Drug Dev. Technol. 4, 653–660 (2006). · doi:10.1089/adt.2006.4.653
  21. Sanz, A. et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS ONE 6, e18522 (2011). · DOI
  22. Olow, A. et al. An atlas of the human kinome reveals the mutational landscape underlying dysregulated phosphorylation cascades in cancer. Cancer Res. 76, 1733–1745 (2016). · DOI · Paper page
  23. Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015). · DOI · Paper page
  24. Yang, X. et al. Widespread expansion of protein interaction capabilities by alternative splicing. Cell 164, 805–817 (2016). · DOI · Paper page
  25. Van Geel, R. M., Beijnen, J. H., Bernards, R. & Schellens, J. H. Treatment individualization in colorectal cancer. Curr. Colorectal Cancer Rep. 11, 335–344 (2015). · DOI
  26. Ursem, C., Atreya, C. E. & Van Loon, K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest. Cancer 8, 13–23 (2018).
  27. Bernards, R. A missing link in genotype-directed cancer therapy. Cell 151, 465–468 (2012). · DOI
  28. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Eng. J. Med. 371, 1867–1876 (2014). · DOI · Paper page
  29. Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94–109 (2014). · DOI · Paper page
  30. Kemper, K. et al. BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Rep. 16, 263–277 (2016). · DOI · Paper page
  31. Janne, P. A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709–723 (2009). · DOI · Paper page
  32. Ruiz-Saenz, A. & Moasser, M. M. Targeting HER2 by combination therapies. J. Clin. Oncol. 36, 808–811 (2018). · DOI
  33. Cohen, R. L. & Settleman, J. From cancer genomics to precision oncology—tissue’s still an issue. Cell 157, 1509–1514 (2014). · DOI
  34. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013). · DOI · Paper page
  35. Kemper, K. et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104–1118 (2015). · DOI · Paper page
  36. Breitinger, H.-G. Drug Synergy—Mechanisms and Methods of Analysis (InTech, 2012). · DOI
  37. Chou, T. C. & Talalay, P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27–55 (1984). · DOI · Paper page
  38. Berenbaum, M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin. Exp. Immunol. 28, 1–18 (1977).
  39. Berenbaum, M. C. What is synergy? Pharmacol. Rev. 41, 93–141 (1989).
  40. Bliss, W. L. Early man in western and northwestern Canada. Science 89, 365–366 (1939). · doi:10.1126/science.89.2312.365-a
  41. Arao, T. et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 64, 9101–9104 (2004). · DOI
  42. Daemen, A. et al. Modeling precision treatment of breast cancer. Genome Biol. 14, R110 (2013). · DOI · Paper page
  43. Moasser, M. M., Srethapakdi, M., Sachar, K. S., Kraker, A. J. & Rosen, N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 59, 6145–6152 (1999).
  44. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010). · DOI · Paper page
  45. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010). · DOI · Paper page
  46. Mori, M., Pan, B. & Coppé, J. P. High-throughput kinase activity mapping (HT-KAM) system: biochemical assay. Nat. Protoc. Exch. https://doi.org/10.1038/protex.2019.029 (2019). · DOI · Paper page
  47. Yau, C., Wolf, D. M. & Coppé, J. P. High-throughput kinase activity mapping (HT-KAM) system: analysis of phospho-catalytic profiles. Nat. Protoc. Exch. https://doi.org/10.1038/protex.2019.030 (2019). · DOI · Paper page

Cited by

See all 36

Metadata

Authors
Coppé, J.-P., Mori, M., Pan, B., Yau, C., Wolf, D. M., Ruiz-Saenz, A., Brunen, D., Prahallad, A., Cornelissen-Steijger, P., Kemper, K., Posch, C., Wang, C., Dreyer, C. A., Krijgsman, O., Lee, P. R. E., Chen, Z., Peeper, D. S., Moasser, M. M., Bernards, R., & van ‘t Veer, L. J.
Venue
Nature Cell Biology
Published
2019-06
Volume
21
Issue
6
Pages
778-790
ISSN
  • 1465-7392
  • 1476-4679
Cited by
36
References
23
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. https://app.cochat.ai/papers/10.1038/s41556-019-0328-z
The paper
Coppé, J.-P., Mori, M., Pan, B., Yau, C., Wolf, D. M., Ruiz-Saenz, A., Brunen, D., Prahallad, A., Cornelissen-Steijger, P., Kemper, K., Posch, C., Wang, C., Dreyer, C. A., Krijgsman, O., Lee, P. R. E., Chen, Z., Peeper, D. S., Moasser, M. M., Bernards, R., & van ‘t Veer, L. J. (2019). Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature Cell Biology. https://doi.org/10.1038/s41556-019-0328-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.